Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06252610 · ClinicalTrials.gov registry record
PET/MRI of Primary Sclerosing Cholangitis
A clinical trial, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- 10
- Enrollment target
NCT06252610: Clinical Trial study, sponsored by Massachusetts General Hospital.
NCT06252610 is a clinical trial that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06252610 has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- 10 participants
- Enrollment target
Study Summary
This study aims to use positron emission tomography (PET)/magnetic resonance imaging (MRI) to diagnose and quantify PSC-related biliary tract fibrosis and to improve upon the currently available non-invasive diagnostic capabilities by investigating the ability of combined PET/MRI to detect and quantify fibrosis using a novel collagen-binding radiotracer. Specifically, the investigators will be comparing \[68Ga\]CBP8- and \[18F\]-FAPI-74 PET/MRI to a liver transient elastography scan in the diagnosis of biliary tree fibrosis.
Interventions
- DRUG Radiotracer Injection
- DIAGNOSTIC_TEST Imaging
- DRUG Contrast Media, Magnetic Resonance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-05-10 |
| Est. Completion | 2029-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06252610
The ClinicalTrials.gov registry entry for NCT06252610 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiotracer Injection is the first listed.
NCT06252610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06252610 about?
NCT06252610 is a clinical study titled "PET/MRI of Primary Sclerosing Cholangitis". This study aims to use positron emission tomography (PET)/magnetic resonance imaging (MRI) to diagnose and quantify PSC-related biliary tract fibrosis and to improve upon the currently available non-invasive diagnostic capabilities by investigating the ability of combined PET/MRI to detect and quant...
What is the current status of trial NCT06252610?
This trial is currently not yet recruiting. The enrollment target is 10 participants. The study started on 2026-05-10. Estimated completion is 2029-04-30.
What interventions are being tested in trial NCT06252610?
The interventions under investigation include: Radiotracer Injection (DRUG), Imaging (DIAGNOSTIC_TEST), Contrast Media, Magnetic Resonance (DRUG).
Who is sponsoring clinical trial NCT06252610?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.